Telix Pharmaceuticals Company Description
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases.
The company operates through three segments: Therapeutics, Precision Medicine, and Telix Manufacturing Solutions.
It offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis.
The company’s products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX007-CDx, a cold kit for the preparation of imaging for prostate cancer; TLX66-CDx to treat bone marrow conditioning.
It also TLX250 for the treatment of clear cell renal cell carcinoma; TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning.
In addition, the company develops TLX300 for the treatment of soft tissue sarcoma; TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX090, a bone-seeking agent for bone metastases and pain palliation.
Further, it operates in Australia, New Zealand, Belgium, Japan, Switzerland, Germany, the United Kingdom, Canada, Singapore, Austria, Spain, France, and the United States.
Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
| Country | Australia |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 234 |
| CEO | Christian Behrenbruch |
Contact Details
Address: 55 Flemington Road North Melbourne, VIC 3051 Australia | |
| Phone | 61 3 9093 3855 |
| Website | telixpharma.com |
Stock Details
| Ticker Symbol | TLPPF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | AUD |
| ISIN Number | AU000000TLX2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Valeix M.B.A. | Chief Executive Officer of Telix Therapeutics |
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, MD, Group Chief Executive Officer and Executive Director |
| Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer |
| Darren Patti Pharm.D. | Group Chief Operating Officer |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor |
| Dr. David N. Cade M.B.A., M.D., MBBS | Group Chief Medical Officer |
| Dr. Paul Schaffer | Chief Technology Officer |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist |
| Craig Ulrick | Chief Information Officer |
| Kyahn Williamson B.A. | Senior Vice President of Corporate Communications and Investor Relations |